MucoLife Therapeutics secures €91K from Vinnova to scale manufacturing of COPD treatment

MucoLife Therapeutics has received €91,000 (SEK 1 million) from Vinnova, Sweden’s innovation agency, through the call “Support to small and medium-sized companies for the use of life science infrastructure.” The funding supports establishing a scalable manufacturing process for MLT-001, the company’s first-in-class inhaled peptide designed to dissolve airway mucus plugs in chronic obstructive pulmonary disease (COPD). Check out our earlier interview with Thaher Pelaseyed, co-founder and…